27 completed, 11 recruiting, 7 terminated, 4 active not recruiting. 59 Phase 1, 21 Phase 2.
Follow Brain Tumor: new trials by email Literature Review of Brain Tumor trials Research Report on Brain Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Panitumumab-IRDye800 to Detect Pediatric Neoplasms During Neurosurgical Procedures Panitumumab-IRDye800, Pinpoint-IR9000 endoscopic/handheld device, Explorer Air camera - Brain Tumor | Phase 1 / Phase 2 | Recruiting | Stanford University | 12 | 2026-12-01 | 2026-09-29 |
| B7-H3.CD28Z.CART in CNS Neoplasms B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Central Nervous System Neoplasms, Brain Tumor | Phase 1 | Recruiting | Robbie Majzner | 70 | 2026-09-01 | 2026-09-03 |
| Magnetic Resonance Fingerprinting Guided Extended Resection in Glioblastomas Control Group - Standard of care neurosurgical resection, MRF/MRI infiltration guidance for extended resection - Glioblastoma, Brain Tumor | Phase 1 | Withdrawn | Case Comprehensive Cancer Center | 2025-12-01 | 2026-07-01 | |
| A PROSPECTIVE, SINGLE-CENTERED, ASSESSOR-BLINDED STUDY TO EVALUATE THE CLINICAL EFFICACY OF THE PROPOSED CELL/TISSUE HISTOPATHOLOGY PROCESSOR CCELL (CONFOCAL FLUORESCENCE ENDOMICROSCOPY) FOR INTRAOPERATIVE DIAGNOSIS IN BRAIN TUMORS cCeLL In vivo, Indocyanine Green - Frozen Sections, Indocyanine Green (ICG) | Phase 1 | Not yet recruiting | VPIX Medical | 30 | 2025-12-01 | 2025-11-28 |
| Multi-center Study on CCeLL-In Vivo's Clinical Efficacy for Intraoperative Brain Tumor Diagnosis. cCeLL In vivo, Indocyanine Green - Frozen Sections, Indocyanine Green | Phase 1 | Not yet recruiting | VPIX Medical | 100 | 2025-06-01 | 2025-03-10 |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss TNG456, abemaciclib - Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme | Phase 1 / Phase 2 | Recruiting | Tango Therapeutics, Inc. | 191 | 2025-03-24 | 2026-10-21 |
| Brodalumab in the Treatment of Immune-Related Adverse Events Brodalumab, CT scan - Breast Cancer, Esophageal Cancer | Phase 1 | Recruiting | Brian Henick, MD | 11 | 2025-03-11 | 2026-05-13 |
| A Study of Sotorasib in People With Brain Tumors Sotorasib - Brain Tumor | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 16 | 2025-01-29 | 2026-05-22 |
| Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM) NaviFUS System, Lumason, Bevacizumab - Glioblastoma Multiforme, Glioblastoma | Phase 1 / Phase 2 | Suspended | NaviFUS Corporation | 10 | 2024-10-22 | 2026-09-09 |
| TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas Tumor Infiltrating Lymphocytes (TIL), Cyclophosphamide, Fludarabine - Brain Tumor, Brain Metastases | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 85 | 2024-10-20 | 2024-11-05 |
| 000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations Zotiraciclib - Brain Tumor, Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 96 | 2023-05-16 | 2026-11-12 |
| A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors tepotinib, tepotinib plus osimertinib - Brain Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2023-02-27 | 2024-04-17 | |
| Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) Exablate, Doxorubicin - Brain Tumor | Phase 1 / Phase 2 | Active not recruiting | InSightec | 10 | 2023-01-04 | 2026-04-17 |
| Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG Exablate, Doxorubicin - Brain Tumor | Phase 1 / Phase 2 | Active not recruiting | InSightec | 10 | 2023-01-04 | 2026-04-21 |
| Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma. Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery (fSRS) - Malignant Glioma of Brain, Astrocytoma | Phase 1 | Recruiting | Henry Ford Health System | 18 | 2022-11-29 | 2025-12-16 |
| A Study of Maprotiline in Combination With Tamoxifen and Temozolomide for Recurrent Glioblastoma Temozolomide, Tamoxifen, Maprotiline - Glioblastoma, Brain Tumor | Phase 1 | Withdrawn | University of Rochester | 2022-06-01 | 2022-08-22 | |
| Prehabilitation, Rehabilitation and Comprehensive Approach to the Sequelae of Brain Tumors Non-invasive neuromodulation (TMS and/or tDCS) - Brain Tumor | Phase 1 | Unknown | Institut Guttmann | 20 | 2021-06-21 | 2023-05-06 |
| Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 - Liver Cancer, Lung Cancer | Phase 1 | Recruiting | Second Affiliated Hospital of Guangzhou Medical University | 40 | 2021-01-01 | 2024-06-25 |
| WP1066 in Children With Refractory and Progressive or Recurrent Malignant Brain Tumors WP1066 - Brain Tumor, Medulloblastoma | Phase 1 | Completed | Emory University | 10 | 2020-05-04 | 2023-02-21 |
| Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM Tumor Treating Fields, Temozolomide, Radiation Therapy - Glioblastoma, Cancer of Brain | Phase 1 | Terminated | Providence Health & Services | 7 | 2019-12-02 | 2024-03-04 |
Showing 20 of 59. Sign in to see all of them.
Brain Neoplasms (59) · Glioblastoma (28) · Glioma (13) · Astrocytoma (11) · Neoplasms (8) · Central Nervous System Neoplasms (6) · Medulloblastoma (6) · Ependymoma (5) · Recurrence (5) · Meningioma (4) · Oligodendroglioma (4) · Breast Neoplasms (3) · Liver Neoplasms (3) · Lung Neoplasms (3) · Lymphoma (3)
Brain Diseases (59) · Central Nervous System Diseases (59) · Neoplasms by Site (59) · Nervous System Diseases (59) · Nervous System Neoplasms (59) · Central Nervous System Neoplasms (53) · Neoplasms (51) · Neoplasms by Histologic Type (39) · Neoplasms, Glandular and Epithelial (36) · Neuroectodermal Tumors (36) · Neoplasms, Germ Cell and Embryonal (35) · Neoplasms, Nerve Tissue (35) · Neoplasms, Neuroepithelial (35) · Glioma (21) · Astrocytoma (19)
Temozolomide (10) · Bevacizumab (4) · Cyclophosphamide (4) · Carboplatin (2) · Doxorubicin (2) · Filgrastim (2) · Gemcitabine (2) · Granulocyte Colony-Stimulating Factor (2) · Imiquimod (2) · Indocyanine Green (2) · Interleukin-2 (2) · Lomustine (2) · Radiotherapy (2) · Vorinostat (2) · fludarabine (2)
National Cancer Institute (NCI) (5) · Dana-Farber Cancer Institute (3) · Northwell Health (3) · InSightec (2) · M.D. Anderson Cancer Center (2) · Memorial Sloan Kettering Cancer Center (2) · Providence Health & Services (2) · St. Jude Children's Research Hospital (2) · VPIX Medical (2) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · BioTex, Inc. (1) · Brian Henick, MD (1) · Case Comprehensive Cancer Center (1) · Catherine Bollard (1)
United States (45) · China (4) · Canada (2) · France (2) · Netherlands (2) · Australia (1) · New Zealand (1) · Puerto Rico (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
David S Shulman, MD (2) · Giles W. Robinson, MD (2) · John Boockvar, MD (2) · Adam Crystal, MD, PhD (1) · Ahmed Idbaih, MD, PhD (1) · Alexandre Carpentier, M.D./ Ph.D. (1) · Andrew Sloan, MD (1) · Barbara O'Brien, MD (1) · Behnam Badie (1) · Brian Henick, MD (1) · Bruce M Frankel, MD (1) · Carl Langberg, MD, PhD (1) · Chaitra Badve, MD (1) · Christopher Moertel, MD (1) · Clemens Dirven, MD PhD (1)
PMID 18497327, PMID 22109661, PMID 23560574, PMID 23817721, PMID 24297161, PMID 26645405, PMID 28057014, PMID 30717050, PMID 32373649, PMID 33312759, PMID 34862245, PMID 35022322, PMID 37786680, PMID 37823909, PMID 37849833, PMID 37853118, PMID 38853689, PMID 40241769, PMID 41308010, PMID 41379553, PMID 41679299, PMID 42380677
2014 (1), UL1TR000064 (1)